What Research is Being Discussed for DLBCL at ASH 2024?

There are many research publications being presented at the ASH 2024 conference for diffuse large B-cell lymphoma (DLBCL). Read about some of the session topics for today. Stay tuned for coverage of these topics at HealthTree Conference Coverage in the upcoming weeks. 

Progress and Challenges of DLBCL Treatments 

In a morning session titled “Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma,” some of the topics discussed included:

• Based on 5 years of follow-up data from the POLARIX study, how effective is an antibody-drug conjugate (ADC) called polatuzumab (Polivy by Genentech) in combination with R-CHOP for DLBCL?
• Looking at data surrounding the CAR T-cell therapy liso-cel (Breyanzi by BMS) for DLBCL.
• Reviewing how effective bispecific antibodies are for DLBCL if CAR T-cell therapy doesn’t work. 

CAR T-cell Therapy Safety and Outcomes for DLBCL 

In the afternoon session titled “Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies,” some of the topics presented included: 

• Information about tisa-cel (Kymriah by Novartis) for relapsed/refractory DLBCL.
• Reviewing the risk level of side effects from CAR T-cell therapy and BiTE therapy, such as cytokine release syndrome and brain-related side effects.
• Evaluating the differences between using CAR T-cell therapy as a second treatment or a later line of therapy for DLBCL. 

Additional Popular Topics 

Other highlights from ASH 2024 for relapsed/refractory DLBCL to watch news coverage for include: 

• Reviewing the effectiveness and safety of a bispecific antibody called odronextamab (Ordspono by Regeneron) when used by itself for DLBCL patients whose cancer progressed after prior CAR T-cell therapy.
• Updates on a CAR T-cell therapy called rapca-cel (YTB323 by Novartis).
• Discussing the results of a CAR T-cell therapy called zamto-cel (by Miltenyi Biomedicine) that attaches to two sites on a cancer cell instead of one.
• Evaluating data of how effective CD22 CAR T-cell therapy is for LBCL after CD19 CAR T-cell therapy (different surface proteins on the cancer cell CAR T attaches to).
• Reviewing the safety differences between types of chemotherapy used as a pre-treatment to CAR T-cell therapy.
• Data from the CAR T-cell therapy axi-cel (Yescarta by Kite) as a second treatment.
• Bispecific antibody mosunetuzumab (Lunsumio by Genentech) in combination with polatuzumab.

Stay Tuned! 

We’re excited to cover this important information on your behalf in the upcoming weeks, writing in a way that is easy to understand. Bookmark the link below to view the news about published conference coverage. 

HealthTree Conference Coverage

Sources: 

• Aggressive Lymphomas: Clinical and Epidemiological: CARs, Bispecifics, and ADCs: Progress and Challenges in Aggressive B Cell Lymphoma
• Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Driving the CARs Home: Real-World Safety and Outcomes of CAR-T Cell Therapies
• Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study
• Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update
• Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
• CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
• Real World Comparison of Efficacy and Safety of Fludarabine-Versus Bendamustine-Based Lymphodepleting Chemotherapy for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Relapse/Refractory (r/r) Large B-Cell Lymphoma (LBCL)
• Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
• A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)